When was PreOmics founded?

PreOmics was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is PreOmics located?

PreOmics is headquartered in Munich, Germany.

Who is the current CEO of PreOmics?

Garwin Pichler and Nils Kulak s of PreOmics. Nils Kulak has also founded 1 company.

Which legal entities is PreOmics associated with?

PreOmics is associated with PreOmics GmbH and 1 other.

How many employees does PreOmics have?

As of May 31, 2026, the latest employee count at PreOmics is 56.

Is PreOmics a funded company?

PreOmics is a funded company, having raised a total of $19.1M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2015.

When was the latest funding round of PreOmics?

PreOmics' latest funding was a $***** Series B round on Jan 18, 2022, with participation from 1 investor.

Where does PreOmics rank among its competitors?

PreOmics ranks 4th amongst 127 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was PrognomiQ, which secured $11.9M in Jan, 2026.

Who are the top competitors of PreOmics?

PreOmics' top competitors include PrognomiQ, Toyobo and LenioBio. Among them, PrognomiQ secured the most recent funding round in January, 2026.

PreOmics - 2026 Company Profile, Team, Funding, Competitors & Financials

PreOmics is a series B company based in Munich (Germany), founded in 2014 by Garwin Pichler and Nils Kulak. It operates as a Provider of reagents and instruments for proteomics research. PreOmics has raised $19.1M in funding from investors like Bruker, HTGF and Think.Health. The company has 127 active competitors, including 13 funded and 17 that have exited. Its top competitors include companies like PrognomiQ, Toyobo and LenioBio.

Company Details

Provider of reagents and instruments for proteomics research. The company currently manufactures sample preparation kits for reproducible preparation of clean peptide mixtures from any starting material and accessories for proteomics research. There is also a pre-fractionation system under development called SPIDER which the company claims, will be the first nano-flow fully automated peptide pre-fractionation device.

Website: www.preomics.com/
Social
Email ID: *****@preomics.com
Phone Number: +49 **********

Key Metrics

Founded Year

2014

Location

Munich, Germany

Stage

Series B

Total Funding

$19.1M in 7 rounds

Latest Funding Round

Series B, Jan 18, 2022, $*****

Investors

Bruker & 24 more

Ranked

4^th among 127 active competitors

Employee Count

56 as on May 31, 2026

Similar Companies

PrognomiQ & 154 more

View PreOmics' full profile

PreOmics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PreOmics GmbH CIN: HRB222988 , Germany, Active	Jan 13, 2016	-	22 (As on Dec 31, 2020)
Preomics Gmbh CIN: 0780.732.313 , Belgium, Active	Feb 01, 2022	-	-	-

PreOmics has raised a total funding of $19.1M over 7 rounds. Its first funding round was on 2015. Its latest funding round was a Series B round on Jan 18, 2022 for $*****. 1 investor participated in its latest round. PreOmics has 10 institutional investors and 15 angel investors.

Here is the list of recent funding rounds of PreOmics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 18, 2022	6885031	Series B	3305806	8911701	3673215	9858945
Aug 31, 2019	4390201	Grant (prize money)	9165004	8941577	5043181	EIC Fund
May 01, 2019	2279025	Grant (prize money)	3186700	1999987	9766730	Europa

Access funding benchmarks and valuations. Sign up today!

View details of PreOmics's funding rounds and investors

The founders of PreOmics are Garwin Pichler and Nils Kulak. Nils Kulak is the CEO of PreOmics.

Here are the details of PreOmics' key team members:

Garwin Pichler: Co-Founder & Co-CEO of PreOmics.
Nils Kulak: Co-Founder & CEO of PreOmics.
Contact Info: 1 email address

View details of PreOmics's Founder profiles and Board Members

PreOmics' employee count trend

PreOmics has 56 employees as of May 26. Here is PreOmics's employee count trend over the years:

Uncover PreOmics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PreOmics include PrognomiQ, Toyobo and LenioBio. Here is the list of Top 10 competitors of PreOmics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PrognomiQ 2020, San Mateo (United States), Series D	Developer of tests for the detection and treatment of cancer and other diseases	$135M	Bruker, Seer & 9 others	63/100
2nd	Toyobo 1882, New York City (United States), Public	Provider of functional polymers, industrial materials, and healthcare products	-	-	57/100
3rd	LenioBio 2016, Dusseldorf (Germany), Series A	Provider of kit for cell-free protein expression for accelerating drug delivery	$13M	Bridford Group, Eureka & 7 others	56/100
4th	PreOmics 2014, Munich (Germany), Series B	Provider of reagents and instruments for proteomics research	$19.1M	Think.Health, FOUNDER.org & 23 others	55/100
5th	Navinci Diagnostics 2004, Uppsala (Sweden), Series A	Developer of products for the detection and quantification of proteins	$8.49M	Segulah Medical Acceleration, Landegren Gene Technology ... & 3 others	54/100
6th	List Biological Laboratories 1978, Campbell (United States), Acquired	Specializes in the production of research reagents	$48.4M	Korea Investment Value Asset Management, DSC Investment ... & 1 others	49/100
7th	ACRO Biosystems 2016, Newark (United States), Funding Raised	Provider of innovative tools and solutions for biopharmaceutical research and development	-	Puhua Capital, Share Capital	47/100
8th	Expedeon 2003, Swavesey (United Kingdom), Acqui-Hired	Reagents and kits for protein-based research	$390K	Dievini, Santander Bank & 2 others	42/100
9th	Cellvoyant 2021, United Kingdom, Seed	Developer of AI-driven cell analytics platform and process optimisation services	$11.9M	Octopus Ventures, Air Street Capital & 7 others	40/100
10th	Rekom Biotech 2011, Granada (Spain), Funding Raised	Recombinant antigen for IVD industry	-	CDTI	40/100